JP/ZH: Currently, only the Luminex LTG section and the Service & Support pages regarding Luminex LTG are available in Japanese/Chinese.
31/07/26 - 12:50
Revenue and EBITDA Supported by Strong Q2 Growth in the First Half of the Year. 2026 Guidance Confirmed. (277.39 KB)
20/05/26 - 11:16
Diasorin Board of Directors approves the 2026-2030 Business Plan (246.32 KB)
08/05/26 - 17:54
Revenues and EBITDA in line with the expected quarterly revenue trend and impacted by a weak flu season. 2026 Guidance confirmed (256.38 KB)
20/03/26 - 17:44
Revenues and EBITDA growth in line with FY 2025 Guidance. Proposed ordinary dividend per share of €1.30, +8.3% vs 2024 (349.08 KB)
27/10/22 - 13:44
Revenue growth and strong profitability in the first 9 months of 2022 - Full year 2022 Guidance revised upwards (316.32 KB)
03/08/22 - 12:26
Strong revenues growth in the First Half of 2022 - Full Year 2022 Guidance on both Revenues and Profitability revised upwards (316.69 KB)
06/05/22 - 16:45
Strong growth in revenues and cash flow generation in Q1 2022 - Full Year 2022 Guidance revised upwards (467.24 KB)
16/03/22 - 17:39